Teva Neuroscience, Inc.
17
0
0
15
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
5.9%
1 terminated/withdrawn out of 17 trials
93.8%
+7.2% vs industry average
59%
10 trials in Phase 3/4
27%
4 of 15 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Comparison of 1.5T vs. 3T Protocols After Treatment With Glatiramer Acetate (GA)
Role: collaborator
A Study to Evaluate the Impact of Using Warm Compress Prior to Daily Injections of Copaxone®
Role: lead
Rasagiline as Add on to Dopamine Agonists in the Treatment of Parkinson's Disease
Role: lead
ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects
Role: collaborator
A Double Blind Placebo Controlled Trial Evaluating Rasagiline Effects on Cognition in Parkinson's Disease Patients With Mild Cognitive Impairment Receiving Dopaminergic Therapy
Role: collaborator
Diclofenac Sodium Topical Gel to Reduce Injection Site Discomfort in Patients Taking Glatiramer Acetate
Role: collaborator
A Study Assessing Change in Sense of Smell After Rasagiline Use in Parkinson's Patients
Role: collaborator
Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients
Role: lead
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
Role: collaborator
A Multi-Dose Study to Assess Tolerability, Safety and Pharmacology of hGH-ViaDerm™ System in Adults With GH-Deficiency
Role: lead
Safety and Efficacy of Rasagiline in Restless Legs Syndrome
Role: collaborator
Therapy Optimization in Multiple Sclerosis (MS)
Role: lead
Effectiveness, Tolerability and Safety of Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa
Role: lead
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Role: lead
A Study to Evaluate Readiness to Self-inject on Adherence and Compliance to Copaxone® Therapy
Role: lead
A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone
Role: lead
A Study to Evaluate the Impact on Skin (Injection Site) Reactions of Using Alcohol Wipes Prior to Daily Injections of Copaxone®.
Role: lead
All 17 trials loaded